Skip to main content
SHOUYAO HOLDINGS CO.,LTD logo

SHOUYAO HOLDINGS CO.,LTD — Investor Relations & Filings

Ticker · 688197 ISIN · CNE1000062V6 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-04-17 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688197

About SHOUYAO HOLDINGS CO.,LTD

http://www.shouyaoholding.com/

Shouyao Holdings Co., Ltd. focuses on the discovery and development of innovative small molecule drugs. The company maintains a pipeline primarily targeting oncology, metabolic diseases, and inflammatory conditions. Its core research capabilities encompass drug design, lead optimization, and clinical development. Key candidates in its portfolio include next-generation ALK inhibitors and RET inhibitors designed to address unmet medical needs in lung cancer treatment. The organization utilizes a proprietary technology platform to accelerate the transition from laboratory research to clinical application, aiming to provide high-efficacy and low-toxicity therapeutic solutions.

Recent filings

Filing Released Lang Actions
首药控股（北京）股份有限公司2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "首药控股（北京）股份有限公司2025年年度报告摘要" which translates to "Shouyao Holdings (Beijing) Co., Ltd. 2025 Annual Report Summary." It contains detailed financial data, business overview, clinical trial progress, product pipeline, market analysis, and management discussion. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. It includes audited financial figures, management discussion and analysis, and detailed operational and strategic information typical of an annual report. There is no indication that this is merely an announcement of a report or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K).
2026-04-17 Chinese
首药控股（北京）股份有限公司2025年度审计报告
Audit Report / Information Classification · 95% confidence The document contains a detailed audit report including an auditor's opinion, basis for the opinion, key audit matters, responsibilities of management and auditors, and extensive financial statements such as consolidated and parent company balance sheets, income statements, and cash flow statements for the fiscal year ending December 31, 2025. The presence of an independent auditor's report with audit opinion and detailed financial statements indicates this is a full audit report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the document fits the category of an Audit Report / Information (AR).
2026-04-17 Chinese
首药控股（北京）股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "首药控股（北京）股份有限公司2026年第一季度报告" which translates to "Shouyao Holdings (Beijing) Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the period ending March 31, 2026. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. It is not an announcement or a brief summary but a full report with substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2026-04-17 Chinese
首药控股（北京）股份有限公司2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It is addressed to all shareholders and discusses the evaluation of the company's internal control effectiveness as of December 31, 2025. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and remediation status. It is a specialized report focused on internal control evaluation rather than a general annual or quarterly financial report. The document length is 3638 characters, which is relatively short but contains substantive content about internal control evaluation, not just an announcement or certification. This type of report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and audit committee oversight, which is distinct from a full Annual Report (10-K) or Interim Report (IR). Therefore, the best classification is AR with high confidence.
2026-04-17 Chinese
首药控股（北京）股份有限公司关于第二届董事会第十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 13th meeting of the second board of directors of 首药控股（北京）股份有限公司. It includes voting results on various agenda items such as approval of the 2025 annual report and its summary, the 2025 board work report, the 2025 general manager work report, reports on independent directors' independence, audit committee reports, profit distribution plans, use of idle funds, and remuneration plans for directors and senior management for 2026. It also mentions proposals to be submitted to the 2025 annual shareholders meeting for approval. The document is primarily about board meeting decisions and management information, including remuneration and governance-related matters. It does not contain the full annual report or financial statements but references that these reports are disclosed elsewhere (e.g., Shanghai Stock Exchange website). Therefore, this document is best classified as Board/Management Information (MANG).
2026-04-17 Chinese
首药控股（北京）股份有限公司关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from 首药控股（北京）股份有限公司 regarding the 2025年度利润分配预案 (2025 annual profit distribution plan). It details the company's decision not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into share capital for the year 2025. The document includes references to board meetings, independent director opinions, and regulatory compliance, but it does not contain full financial statements or comprehensive financial performance data. The document is relatively short (1106 characters) and serves as a formal announcement of the profit distribution plan rather than a full annual report or interim report. This type of announcement fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend distribution plans and shareholder information about profit allocation.
2026-04-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.